Dr. Meret Henry, MD
Claim this profileChildren's Hospital of Michigan
Studies Leukemia
Studies Lymphoma
7 reported clinical trials
36 drugs studied
Area of expertise
1Leukemia
t(9;11) positive
inv(16) positive
t(8;21) positive
2Lymphoma
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Meret Henry, MD is currently running
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
More about Meret Henry, MD
Clinical Trial Related7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Meret Henry, MD has experience with
- Cyclophosphamide
- Nivolumab
- Idarubicin
- Daunorubicin
- Doxorubicin
- Cytarabine
Breakdown of trials Meret Henry, MD has run
Leukemia
Lymphoma
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Meret Henry, MD specialize in?
Meret Henry, MD focuses on Leukemia and Lymphoma. In particular, much of their work with Leukemia has involved t(9;11) positive patients, or patients who are inv(16) positive.
Is Meret Henry, MD currently recruiting for clinical trials?
Yes, Meret Henry, MD is currently recruiting for 3 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Meret Henry, MD has studied deeply?
Yes, Meret Henry, MD has studied treatments such as Cyclophosphamide, Nivolumab, Idarubicin.
What is the best way to schedule an appointment with Meret Henry, MD?
Apply for one of the trials that Meret Henry, MD is conducting.
What is the office address of Meret Henry, MD?
The office of Meret Henry, MD is located at: Children's Hospital of Michigan, Detroit, Michigan 48201 United States. This is the address for their practice at the Children's Hospital of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.